Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS
- 1 March 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (4) , 399-409
- https://doi.org/10.1097/00002030-199804000-00009
Abstract
To determine the safety and efficacy of the sulphated polysaccharide, dextrin 2-sulphate, when delivered to the lymphatic circulation by the peritoneal route. An open Phase I/II dose-escalation clinical study in which six patients with AIDS were treated with seven courses of dextrin 2-sulphate each lasting 1 month. During each course of treatment, the drug was administered daily for 28 days using an intraperitoneal catheter. Viral load was measured at frequent intervals using a plasma tissue culture infectious dose (TCID) assay, a cellular TCID assay, p24 antigenaemia, HIV-1 RNA and HIV-1 DNA. Plasma β-chemokine levels were also measured. Dose escalation was completed without toxicity. A total of 7 patient-months of treatment were completed. With increasing doses of dextrin 2-sulphate, the infectious plasma viraemia, cellular viraemia and p24 antigenaemia all fell during the period of drug administration, but with no significant change in HIV-1 RNA. This was associated with increased plasma levels of macrophage inflammatory protein (MIP)-1α and MIP-1β. Dextrin 2-sulphate accumulated in peritoneal macrophages and induced the release of MIP-1α and MIP-1β from these cells in vitro. These β-chemokines could have augmented the cell surface-mediated anti-HIV-1 effect of dextrin 2-sulphate in vivo by binding to and blocking the CC-chemokine receptor-5. A second fall in infectious plasma viraemia, cellular viraemia, p24 antigenaemia and HIV-1 RNA was seen at day 100 which was then sustained for several months. A clinical improvement in Kaposi's sarcoma was also seen. Our results suggest that the intraperitoneal administration of dextrin 2-sulphate can reduce the replication of HIV-1 in patients with AIDS. With increasing doses of dextrin 2-sulphate, the fall in viral load was seen during the period of drug administration and again 2 months after completing treatment.Keywords
This publication has 38 references indexed in Scilit:
- Anti-HIV Type 1 Activity of Sulfated Derivatives of Dextrin against Primary Viral Isolates of HIV Type 1 in Lymphocytes and Monocyte-Derived MacrophagesAIDS Research and Human Retroviruses, 1997
- Issues in the Design of Trials of Therapies for Subjects with Human Immunodeficiency Virus Infection that Use Plasma RNA Level as an OutcomeThe Journal of Infectious Diseases, 1997
- Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with >=400 CD4 Lymphocytes: Implications for Applying Measurements to Individual PatientsThe Journal of Infectious Diseases, 1997
- CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5Nature, 1996
- Human Immunodeficiency Virus Type 1 Quantitative Cell Microculture as a Measure of Antiviral Efficacy in a Multicenter Clinical TrialThe Journal of Infectious Diseases, 1995
- Syncytium-Inducing and Non-Syncytium-Inducing Capacity of Human Immunodeficiency Virus Type 1 Subtypes Other Than B: Phenotypic and Genotypic CharacteristicsAIDS Research and Human Retroviruses, 1994
- Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitroAIDS, 1994
- Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral bloodClinical and Experimental Immunology, 1993
- Inhibition of Development of Kaposi's Sarcoma-Related Lesions by a Bacterial Cell Wall ComplexScience, 1992
- Investigations into the Mechanism by Which Sulfated Polysaccharides Inhibit HIV Infection In VitroAIDS Research and Human Retroviruses, 1992